Interní Med. 2008; 10(10): 466-469

AL amyloidosis and heart

MUDr. Tomáš Pika, et al
III. interní klinika FN a LF UP Olomouc

Primary (AL) amyloidosis and its associated organ impairment have an effect on quality and life lenght of the patients. One of the most powerfull prognostic markers is heart affection. Determination of heart affection severity and also treatment management is very difficult, requiring cooperation of many health specialists.

Keywords: Key words: AL amyloidosis, heart, examination methods.

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pika T, al E. AL amyloidosis and heart. Interní Med. 2008;10(10):466-469.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Adam Z, Ščudla V, Válek V, Lukáš Z. AL-amyloidóza a některé další typy amyloidóz. In: Adam Z, Vorlíček J. et al. Hematologie II - Přehled maligních hematologických nemocí, Grada Publishing, Praha 2001: 527-552.
    2. Adam Z, Ščudla V. Amyloidóza. In: Adam Z, Hájek R. et al. Mnohočetný myelom a další monoklonální gamapatie, Masarykova univerzita, Brno 1999: 233-247.
    3. Adam Z, Ščudla V. Klinické projevy a diagnostika AL-amyloidózy a některých dalších typů amyloidózy. Vnitř Lék 2001; 47: 36-45. Go to PubMed...
    4. Aprile C, Marione G, Saponaro R, et al. Cardiac and pleuropulmonary AL amyloid imaging with technetium 99m labelled aprotinin. Eur J Nucl Med 1995; 22: 1393-1401. Go to original source... Go to PubMed...
    5. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 1985; 6: 737-743. Go to original source... Go to PubMed...
    6. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing repipheral blood stem cell transplantation. Blood 2004; 104: 1881-1887. Go to original source... Go to PubMed...
    7. Dispenzieri A, Kyla RA, Gertz MA et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003; 361: 1787-1789. Go to original source... Go to PubMed...
    8. Elbl L. Amyloidóza srdce. In: Adam Z, Hájek R. et al. Mnohočetný myelom a další monoklonální gamapatie, Masarykova univerzita, Brno 1999: 67-70.
    9. Gertz MA, Brown ML, Hauser MF, et al. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis. Arch Intern Med 1987; 147: 1039-1044. Go to original source...
    10. Gertz MA, Comenzo R, Falk RH, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International symposium on amyloid and amyloidosis. Am J Hematol 2005; 79: 319-328. Go to original source... Go to PubMed...
    11. Gregor P. Restriktivní kardiomyopatie. In: Aschermann M. et al. Kardiologie, Galén, Praha 2004: 838-840.
    12. Guidelines on the diagnosis and management of AL amyloidosis. Brit J Hemat 2004; 125: 681-700.
    13. Han S, Chong V, Murray T, et al. Preliminary experience of 99m Tc-Aprotinin scintigraphy in amyloidosis. Eur J Haematol 2007; 79: 494-500. Go to original source... Go to PubMed...
    14. Kyle RA, Greipp PR, O´Fallon WM. Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220-224. Go to original source...
    15. Maceira AM, Joshi J, Prasad SK et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186-193. Go to original source... Go to PubMed...
    16. Modesto KM, Dispenzieri A, Cauduro SA, et al. Left atrial myopathy in cardiac amyloidosis: implication of novel echocardiographic techniques. Eur Heart J 2005; 26: 173-179. Go to original source... Go to PubMed...
    17. Murtagh B, Hamill SC, Gertz MA, et al. Electrocardiographic findings in primary systemis amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 2005; 95: 535-537. Go to original source... Go to PubMed...
    18. Palladini G, Campana C, Klersy C, et al. Serum N-terminal Pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003; 107: 2440-2445. Go to original source... Go to PubMed...
    19. Palladini G, Lavatalli F, Russo P. et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854-3858. Go to original source... Go to PubMed...
    20. Perugini E, Rapezzi C, Piva T, et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92: 343-349. Go to original source... Go to PubMed...
    21. Reyners AKL, Hazenberg BPC, Reitsma WD, et al. Heart rate variability as a predictor of mortality in patients with AA and AL amyloidosis. Eur Heart J 2002; 23: 157-161. Go to original source... Go to PubMed...
    22. Sueyoshi E, Sakamoto I, Okimoto T, et al. Cardiac amyloidosis: typical imaging findings and diffuse myocardial damage demonstrated by delayed contrast-enhanced MRI. Cardiovasc Intervent Radiol 2006; 29: 710-712. Go to original source... Go to PubMed...
    23. Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008; 51: 1022-1030. Go to original source... Go to PubMed...
    24. Weber M, Hamm C. Role of B-type natriuretic paptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92: 843-849. Go to original source... Go to PubMed...
    25. Yagi S, Akaike M, Ozaki S, et al. Improvement of cardiac diastolic function and prognosis after autologous peripheral blood stem cell transplantation in AL cardiac amyloidosis. Internal Med 2007; 1705-1710. Go to original source...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.